
## **Trustees' Annual Report for the period** 

Period start date Period end date Day Month Year Day Month Year **From** 01 01 2024 **To** 31 12 2024 

## Section A                        Reference and administration details 

The Centre for Vision in the Developing World Charitable Foundation 

**Charity name** Foundation **Other names charity is known by** CVDW **Registered charity number (if any)** 1161978 **Charity's principal address** 11 Wood End Little Horwood Milton Keynes **Postcode** MK17 0PE 

**Names of the charity trustees who manage the charity** 

- **Dates acted if not for whole Name of person (or body) entitled** 

- **Trustee name Office (if any) year to appoint trustee (if any)** 

- 1 Joshua Silver chair 2 John Salmon until 31 October 2024 3 Christopher Wray 4 5 6 7 8 9 

- 10 11 12 13 14 15 16 17 

**Names of the trustees for the charity, if any, (for example, any custodian trustees)** 

**Name Dates acted if not for whole year** 

**TAR** 

March **2012** 

1 



|**Names and addresses of advisers (Optional information)**<br>**Type of adviser**<br>**Name**<br>**Address**|**Names and addresses of advisers (Optional information)**<br>**Type of adviser**<br>**Name**<br>**Address**|**Names and addresses of advisers (Optional information)**<br>**Type of adviser**<br>**Name**<br>**Address**|
|---|---|---|
||||
||||
||||
||||



## **Name of chief executive or names of senior staff members (Optional information)** 

## **Section B              Structure, governance and management** 

## **Description of the charity’s trusts** 

constitution 

Type of governing document (eg. trust deed, constitution) charitable incorporated organisation How the charity is constituted 

- (eg. trust, association, company) 

appointed by existing trustees Trustee selection methods 

(eg. appointed by, elected by) 

## **Additional governance issues (Optional information)** 

You **may choose** to include additional information, where relevant, about: 

- policies and procedures adopted for the induction and training of trustees; 

- the charity’s organisational structure and any wider network with which the charity works; 

- relationship with any related parties; 

- trustees’ consideration of major risks and the system and procedures to manage them. 

## **Section C                    Objectives and activities** 

**Summary of the objects of the charity set out in its governing document** 

The advancement of health and the relief of those in need of refractive vision correction in populations which lack access to eye care professionals by undertaking or funding research into self-refraction and the development of improved products based on self-refraction and by providing eyeglasses to such persons either directly or by supplying, training or funding third party distributors. 

**TAR** 

March **2012** 

2 



The charity is developing two major programmes to help people who need glasses but lack access to eye care professionals. Self-refraction using adaptive spectacles offers a scalable solution to this problem and the clinical efficacy and logistical efficiency of such an approach have previously been demonstrated in peer-reviewed clinical trials and pilot distributions throughout the developing world. The charity’s universal access programme aims to establish the availability of glasses to everyone, everywhere at the minimum sustainable cost of delivery. Access to glasses depends on local availability of both a suitable product and the knowledge required to **Summary of the main** identify poor visual acuity and supervise self-refraction. By establishing a **activities undertaken for the** pool of trained volunteers in every region, we can build the capacity to **public benefit in relation to** train local distributors, including teachers in schools or members of other **these objects (include within** local institutions or not-for-profit organisations, or local businesses or **this section the statutory** entrepreneurs selling glasses to their communities. Similarly, by **declaration that trustees have** establishing regional hubs for the warehousing and wholesale supply of **had regard to the guidance** adaptive spectacles, we can ensure the availability of a suitable product **issued by the Charity** to any local distributor. Rather than building our own full distribution **Commission on public** network, the purpose of the universal access programme is to enable a **benefit)** range of approaches to delivery by public sector, commercial and not-forprofit organisations, so that we can learn which are most effective in each given geographical, cultural and economic context. The targeted delivery programme aims to provide glasses at no cost (or subsidised so as to be universally affordable) to the highest priority population, which we have identified as children in developing world schools. The charity will coordinate delivery of adaptive spectacles to children in schools in developing world countries, directly or in collaboration with local partners. 

In designing these programmes, the trustees considered the guidance on public benefit issued by the Charity Commission. 

## **Additional details of objectives and activities (Optional information)** 

You **may choose** to include further statements, where relevant, about: 

- policy on grantmaking; 

- policy programme related investment; 

- contribution made by volunteers. 

**TAR** 

March **2012** 

3 



## Section D                      Achievements and performance 

The charity undertook planning for future training and distribution events **Summary of the main** in Africa and Latin America, including a train-the-trainer programme for **achievements of the charity** vision screening and self-refraction using adaptive spectacles, and **during the year** logistical planning for distributed warehousing of adaptive spectacles. Donations amounting to £444 were received during the financial period. 

**TAR** 

March **2012** 

4 



## **Section E                    Financial review** 

**Brief statement of the charity’s policy on reserves** 

The charity held at least three months’ projected operating costs as cash reserves at all times during the financial period. 

**Details of any funds materially in deficit** 

## **Further financial review details (Optional information)** 

You **may choose** to include additional information, where relevant about: 

- the charity’s principal sources of funds (including any fundraising); 

- how expenditure has supported the key objectives of the charity; 

- investment policy and objectives including any ethical investment policy adopted. 

## **Section F                     Other optional information** 

## **Section G                    Declaration** 

**The trustees declare that they have approved the trustees’ report above.** 

**Signed on behalf of the charity’s trustees** 

## **Signature(s)** 


**Full name(s)** Joshua Silver **Position (eg Secretary, Chair,** Chairman **etc) Date** 29 October 2025 

**TAR** 

March **2012** 

5 



||**The Centre for Vision in the Developing World**<br>**Charitable Foundation**|**The Centre for Vision in the Developing World**<br>**Charitable Foundation**|**The Centre for Vision in the Developing World**<br>**Charitable Foundation**|**1161978**|**1161978**|**1161978**|**CC16a**|
|---|---|---|---|---|---|---|---|
||**For the period**<br>**from**|01/01/24|**To**||31/12/24|||
|||||||||
|**Section A Receipts and payments**||||||||
|**A1 Receipts**|**Unrestricted**<br>**funds**<br>**to the nearest      £**<br>**444**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br> <br> <br>**444**<br>**-**<br>**-**<br> **-**<br> **444**<br>**-**<br>**144**<br>**-**<br>**-**<br>**597**<br>**-**<br>**-**<br>**-**<br>**-**<br> **741**<br>**-**<br> **-**<br> **741**<br>**-                      297**<br>**-**<br>**6,743**<br>**6,446**|**Restricted**<br>**funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Endowment**<br>**funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**||**Total funds**<br>**to the nearest £**<br>**444**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**444**<br>**-**<br>**-**<br>**-**<br>**444**<br>**-**<br>**144**<br>**-**<br>**-**<br>**597**<br>**-**<br>**-**<br>**-**<br>**-**<br>**741**<br>**-**<br>**-**<br>**-**<br>**741**<br>**-                      297**||**Last year**<br>**to the nearest £**|
|Donations|**444**||||||**576**|
|Interest|**-**||||||**-**|
||**-**||||||**-**|
||**-**||||||**-**|
||**-**||||||**-**|
||**-**||||||**-**|
||**-**||||||**-**|
||**-**||||||**-**|
|**_Sub total_**_(Gross income for_<br>_AR)_|<br> <br>**444**||||||**576**|
|||||||||
|**A2 Asset and investment sales,**<br>**(see table).**||||||||
||**-**|||||||
||**-**||||||**-**|
|**_Sub total_**|**-**||||||**-**|
|**_Total receipts_ **<br>**A3 Payments**||||||||
||||||||**576**|
|||||||||
|Wages, payroll taxes, pension contributions,<br>consultancy fees|**-**||||||**-**|
|Insurance, accountancy, legal, bank fees|**144**||||||**164**|
|Cost ofglassesproduction, shipping|**-**||||||**-**|
|Travel expenses|**-**||||||**-**|
|Telephone, internet|**597**||||||**670**|
||**-**||||||**-**|
||**-**||||||**-**|
||**-**||||||**-**|
||**-**||||||**-**|
|**_Sub total_ **|**741**||||||**834**|
|||||||||
|**A4 Asset and investment**<br>**purchases, (see table)**||||||||
|**Purchase of fixed assets**|**-**||||||**-**|
|||||||||
|**_Sub total_ **|**-**||||||**-**|
|**_Total payments_ **<br>**_Net of receipts/(payments)_**<br>**A5 Transfers between funds**<br>**A6 Cash funds last year end**<br>**_Cash funds this year end_**||||||||
||||||||**834**|
|||||||||
||**-                      297**|**-**|**-**||**-                      297**||**-                     258**|
||**-**|**-**|**-**||**-**||**-**|
||**6,743**|**-**|**-**||**6,743**||**7,002**|
||**6,446**|**-**|**-**||**6,446**||**6,743**|



CCXX R1 accounts (SS) 

29/10/2025 

1 



## **Section B Statement of assets and liabilities at the end of the period** 

|**Categories**<br>Signed by one or two trustees on behalf<br>of all the trustees<br>**B1 Cash funds**<br>**B2 Other monetary assets**<br>**B3 Investment assets**<br>**B4 Assets retained for the**<br>**charity’s own use**<br>**B5 Liabilities**<br>CCXX R2 accounts (SS)|**Details**<br>Bank accounts<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))<br>**Details**<br>**Details**<br>**Details**<br>**Details**<br>Signature<br>2|**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**to nearest £**<br>**to nearest £**<br>**6,446**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**6,446**<br>**-**<br>OK<br>OK<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**to nearest £**<br>**to nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**asset belongs**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**asset belongs**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**liability relates**<br>**Amount due**<br>**(optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Print Name<br>Joshua Silver|**Endowment**<br>**funds**<br>**to nearest £**|
|---|---|---|---|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||OK|
||||**Endowment**<br>**funds**<br>**to nearest £**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**When due**<br>**(optional)**|
|||||
|||||
|||||
|||||
|||||
|||||
||||Date of<br>approval|
||||29/10/2024|
|||||
||||29/10/2025|



